Posted by Michael Wonder on 04 Sep 2024
Unicycive Therapeutics announces submission of the new drug application to the US FDA for oxylanthanum carbonate for the treatment of hyperphosphataemia in patients with chronic kidney disease on dialysis
3 September 2024 - Unicycive Therapeutics today announced that the Company has submitted a new drug application to the US FDA for oxylanthanum carbonate for the treatment of hyperphosphataemia in patients with chronic kidney disease on dialysis.
Unicycive is seeking FDA approval of oxylanthanum carbonate via the 505(b)(2) regulatory pathway.
